Market revenue in 2023 | USD 28.9 million |
Market revenue in 2030 | USD 61.5 million |
Growth rate | 11.4% (CAGR from 2023 to 2030) |
Largest segment | Epinephrine |
Fastest growing segment | Immunotherapies |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 48.1% in 2023. Horizon Databook has segmented the Latin America peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
The peanut allergy treatment market in Latin America presents an interesting scenario. This market is diverse, with varying prevalence of peanut allergy across different countries in the region. In some countries like Brazil and Mexico, peanut allergies are more common, while in others, the prevalence is lower.
In larger countries with a higher prevalence, such as Brazil and Mexico, the peanut allergy treatment market is relatively more significant. These countries have a greater number of patients seeking treatment and management options for peanut allergies. Consequently, they tend to have a broader range of healthcare providers, pharmaceutical companies, and clinics offering specialized treatments.
On the other hand, in smaller countries with lower prevalence rates, the peanut allergy treatment market remains more limited. The number of individuals affected by peanut allergies is smaller, resulting in a less competitive market with fewer specialized service providers.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America peanut allergy treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account